Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LM-101 Monotherapy and Combination Therapy in Advanced Malignant Tumors
NCT05615974Phase 2Recruiting
- Sponsor
- LaNova Medicines
- Start
- Jan 2023
- Primary completion
- Jan 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of LM-101 in advanced malignant solid tumor, lymphoma, sponsored by LaNova Medicines. Started Jan 2023; status: recruiting.
02
Drugs
LM-101
03
Conditions
advanced malignant solid tumorlymphoma
Beyond the preview
Go deeper on NCT05615974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05615974.